利拉鲁肽联合达格列净治疗肥胖2型糖尿病患者的疗效与安全性

Efficacy and Safety of Liraglutide Combined with Dapagliflozin in the Treatment of Obese Patients with Type 2 Diabetes

目的通过利拉鲁肽联合达格列净对肥胖2型糖尿病(type 2 diabetes mellitus,T2DM)患者进行治疗,分析评估其治疗效果以及安全性。方法选取2020年10月—2021年11月临沂市人民医院收治的84例肥胖T2DM患者为研究对象,依照随机数表法分为两组,每组42例。对照组进行利拉鲁肽治疗,研究组使用利拉鲁肽联合达格列净治疗,观察两组患者的肥胖指标、血糖血脂及不良反应的变化情况。结果治疗后,两组患者BMI及腰围的水平较治疗前有所降低,且研究组的BMI及腰围的下降程度大于对照组,差异有统计学意义(P<0.05)。治疗后,研究组的血糖(FPG、2 hPG、HbA1c)水平均显著低于对照组,差异有统计学意义(P<0.05)。治疗后,研究组的TG、TC、LDL-C均低于对照组,HDL-C高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论利拉鲁肽联合达格列净治疗可通过不同的机制有效降低患者的BMI及腰围,还可以降低患者的血糖及血脂水平。此外,两种药物联合使用未增加不良反应发生率,安全性高,治疗效果显著。

Objective To evaluate the efficacy and safety of Liraglutide combined with Dapagliflozin in the treatment of obese patients with type 2 diabetes mellitus(T2DM).Methods 84 obese T2DM patients admitted to Linyi People's Hospital from October 2020 to November 2021 were selected as the study objects and divided into two groups according to random number table method,with 42 cases in each group.The control group was treated with liraglutide,while the study group was treated with liraglutide combined with Dagliazine.The changes of obesity indexes,blood glucose,blood lipids and adverse reactions were observed in the two groups.Results After treatment,the levels of BMI and waist circumference of the two groups were reduced compared with before treatment,and the degree of decline of BMI and waist circumference of the study group was greater than that of the control group,the difference was statistically significant(P<0.05).After treatment,blood glucose levels(FPG,2 hPG,HbA1c)in the study group were significantly lower than those in the control group,the difference was statistically significant(P<0.05).After treatment,TG,TC and LDL-C in the study group were lower than those in the control group,while HDL-C was higher than that in the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Liraglutide combined with Dapagliflozin can effectively reduce the BMI and waist circumference of patients through different mechanisms,and can also reduce the blood glucose and lipid levels of patients.In addition,the combined use of the two drugs did not increase the incidence of adverse reactions,high safety,significant therapeutic effect.